Genprex Preclinical Data Suggests Potential for Lung Cancer Gene Therapy
Event summary
- Genprex collaborators will present three posters at the 2026 AACR Annual Meeting on April 19, 2026.
- Preclinical data identifies TROP2 and PTEN as potential biomarkers for TUSC2 gene therapy resistance in NSCLC.
- Reqorsa® (Quaratusugene ozeplasmid) shows synergistic effects with alectinib in ALK+ NSCLC models.
- TUSC2 restoration enhances NK cell cytotoxicity and antitumor immunity in vivo and in vitro.
The big picture
Genprex's preclinical data positions Reqorsa® as a potential adjunct therapy for lung cancer, particularly in ALK+ NSCLC where resistance to existing treatments is a significant challenge. The identification of biomarkers and the enhancement of NK cell activity suggest a multi-faceted approach to cancer treatment. The company's ongoing clinical trials and FDA designations underscore its strategic focus on developing innovative gene therapies for oncology.
What we're watching
- Clinical Translation
- Whether the preclinical findings will translate into clinical trial success for Reqorsa® in NSCLC.
- Biomarker Validation
- How the identification of TROP2 and PTEN as biomarkers will impact patient selection and treatment strategies.
- Combination Therapy
- The pace at which Genprex can advance combination therapies involving Reqorsa® and existing treatments like alectinib.
Our editorial coverage:
Related topics